Drug firm Dr Reddy’s Laboratories on Tuesday reported a 66.58 per cent rise in its net profit to Rs 570.89 crore for the quarter ended 31 March, 2013 mainly on account of robust sales across all segments.
The company had posted a net profit of Rs 342.70 crore for the corresponding quarter previous fiscal, the company said in a statement. The company’s major segments include global generics, pharmaceutical services and active ingredients.
The company also said that its Board of Directors have recommended a final dividend of Rs 15 per share of Rs 5 face value, for the financial year 2012-13.
The company had posted a net profit of Rs 342.70 crore for the corresponding quarter previous fiscal, the company said in a statement. The company’s major segments include global generics, pharmaceutical services and active ingredients.
The company also said that its Board of Directors have recommended a final dividend of Rs 15 per share of Rs 5 face value, for the financial year 2012-13.